Cell fate determination in cisplatin resistance and chemosensitization

Khanh V. Luong, Ling Wang, Brett J. Roberts, James K Wahl, Aimin Peng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Understanding the determination of cell fate choices after cancer treatment will shed new light on cancer resistance. In this study, we quantitatively analyzed the individual cell fate choice in resistant UM-SCC-38 head and neck cancer cells exposed to cisplatin. Our study revealed a highly heterogeneous pattern of cell fate choices in UM-SCC-38 cells, in comparison to that of the control, non-tumorigenic keratinocyte HaCaT cells. In both UM-SCC-38 and HaCaT cell lines, the majority of cell death occurred during the immediate interphase without mitotic entry, whereas significant portions of UM-SCC-38 cells survived the treatment via either checkpoint arrest or checkpoint slippage. Interestingly, checkpoint slippage occurred predominantly in cells treated in late S and G2 phases, and cells in M-phase were hypersensitive to cisplatin. Moreover, although the cisplatin-resistant progression of mitosis exhibited no delay in general, prolonged mitosis was correlated with the induction of cell death in mitosis. The finding thus suggested a combinatorial treatment using cisplatin and an agent that blocks mitotic exit. Consistently, we showed a strong synergy between cisplatin and the proteasome inhibitor Mg132. Finally, targeting the DNA damage checkpoint using inhibitors of ATR, but not ATM, effectively sensitized UM-SCC-38 to cisplatin treatment. Surprisingly, checkpoint targeting eliminated both checkpoint arrest and checkpoint slippage, and augmented the induction of cell death in interphase without mitotic entry. Taken together, our study, by profiling cell fate determination after cisplatin treatment, reveals new insights into chemoresistance and suggests combinatorial strategies that potentially overcome cancer resistance.

Original languageEnglish (US)
Pages (from-to)23383-23394
Number of pages12
JournalOncotarget
Volume7
Issue number17
DOIs
StatePublished - Apr 26 2016

Fingerprint

Cisplatin
Mitosis
Cell Death
Interphase
Neoplasms
Proteasome Inhibitors
G2 Phase
Head and Neck Neoplasms
S Phase
Keratinocytes
Cell Division
DNA Damage
Cell Line

Keywords

  • Caffeine
  • Cell fate
  • Chemoresistance
  • Cisplatin
  • Mg132

ASJC Scopus subject areas

  • Oncology

Cite this

Cell fate determination in cisplatin resistance and chemosensitization. / Luong, Khanh V.; Wang, Ling; Roberts, Brett J.; Wahl, James K; Peng, Aimin.

In: Oncotarget, Vol. 7, No. 17, 26.04.2016, p. 23383-23394.

Research output: Contribution to journalArticle

Luong, Khanh V. ; Wang, Ling ; Roberts, Brett J. ; Wahl, James K ; Peng, Aimin. / Cell fate determination in cisplatin resistance and chemosensitization. In: Oncotarget. 2016 ; Vol. 7, No. 17. pp. 23383-23394.
@article{5fbb048898c042bdba8848a0d0fef8e6,
title = "Cell fate determination in cisplatin resistance and chemosensitization",
abstract = "Understanding the determination of cell fate choices after cancer treatment will shed new light on cancer resistance. In this study, we quantitatively analyzed the individual cell fate choice in resistant UM-SCC-38 head and neck cancer cells exposed to cisplatin. Our study revealed a highly heterogeneous pattern of cell fate choices in UM-SCC-38 cells, in comparison to that of the control, non-tumorigenic keratinocyte HaCaT cells. In both UM-SCC-38 and HaCaT cell lines, the majority of cell death occurred during the immediate interphase without mitotic entry, whereas significant portions of UM-SCC-38 cells survived the treatment via either checkpoint arrest or checkpoint slippage. Interestingly, checkpoint slippage occurred predominantly in cells treated in late S and G2 phases, and cells in M-phase were hypersensitive to cisplatin. Moreover, although the cisplatin-resistant progression of mitosis exhibited no delay in general, prolonged mitosis was correlated with the induction of cell death in mitosis. The finding thus suggested a combinatorial treatment using cisplatin and an agent that blocks mitotic exit. Consistently, we showed a strong synergy between cisplatin and the proteasome inhibitor Mg132. Finally, targeting the DNA damage checkpoint using inhibitors of ATR, but not ATM, effectively sensitized UM-SCC-38 to cisplatin treatment. Surprisingly, checkpoint targeting eliminated both checkpoint arrest and checkpoint slippage, and augmented the induction of cell death in interphase without mitotic entry. Taken together, our study, by profiling cell fate determination after cisplatin treatment, reveals new insights into chemoresistance and suggests combinatorial strategies that potentially overcome cancer resistance.",
keywords = "Caffeine, Cell fate, Chemoresistance, Cisplatin, Mg132",
author = "Luong, {Khanh V.} and Ling Wang and Roberts, {Brett J.} and Wahl, {James K} and Aimin Peng",
year = "2016",
month = "4",
day = "26",
doi = "10.18632/oncotarget.8110",
language = "English (US)",
volume = "7",
pages = "23383--23394",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

TY - JOUR

T1 - Cell fate determination in cisplatin resistance and chemosensitization

AU - Luong, Khanh V.

AU - Wang, Ling

AU - Roberts, Brett J.

AU - Wahl, James K

AU - Peng, Aimin

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Understanding the determination of cell fate choices after cancer treatment will shed new light on cancer resistance. In this study, we quantitatively analyzed the individual cell fate choice in resistant UM-SCC-38 head and neck cancer cells exposed to cisplatin. Our study revealed a highly heterogeneous pattern of cell fate choices in UM-SCC-38 cells, in comparison to that of the control, non-tumorigenic keratinocyte HaCaT cells. In both UM-SCC-38 and HaCaT cell lines, the majority of cell death occurred during the immediate interphase without mitotic entry, whereas significant portions of UM-SCC-38 cells survived the treatment via either checkpoint arrest or checkpoint slippage. Interestingly, checkpoint slippage occurred predominantly in cells treated in late S and G2 phases, and cells in M-phase were hypersensitive to cisplatin. Moreover, although the cisplatin-resistant progression of mitosis exhibited no delay in general, prolonged mitosis was correlated with the induction of cell death in mitosis. The finding thus suggested a combinatorial treatment using cisplatin and an agent that blocks mitotic exit. Consistently, we showed a strong synergy between cisplatin and the proteasome inhibitor Mg132. Finally, targeting the DNA damage checkpoint using inhibitors of ATR, but not ATM, effectively sensitized UM-SCC-38 to cisplatin treatment. Surprisingly, checkpoint targeting eliminated both checkpoint arrest and checkpoint slippage, and augmented the induction of cell death in interphase without mitotic entry. Taken together, our study, by profiling cell fate determination after cisplatin treatment, reveals new insights into chemoresistance and suggests combinatorial strategies that potentially overcome cancer resistance.

AB - Understanding the determination of cell fate choices after cancer treatment will shed new light on cancer resistance. In this study, we quantitatively analyzed the individual cell fate choice in resistant UM-SCC-38 head and neck cancer cells exposed to cisplatin. Our study revealed a highly heterogeneous pattern of cell fate choices in UM-SCC-38 cells, in comparison to that of the control, non-tumorigenic keratinocyte HaCaT cells. In both UM-SCC-38 and HaCaT cell lines, the majority of cell death occurred during the immediate interphase without mitotic entry, whereas significant portions of UM-SCC-38 cells survived the treatment via either checkpoint arrest or checkpoint slippage. Interestingly, checkpoint slippage occurred predominantly in cells treated in late S and G2 phases, and cells in M-phase were hypersensitive to cisplatin. Moreover, although the cisplatin-resistant progression of mitosis exhibited no delay in general, prolonged mitosis was correlated with the induction of cell death in mitosis. The finding thus suggested a combinatorial treatment using cisplatin and an agent that blocks mitotic exit. Consistently, we showed a strong synergy between cisplatin and the proteasome inhibitor Mg132. Finally, targeting the DNA damage checkpoint using inhibitors of ATR, but not ATM, effectively sensitized UM-SCC-38 to cisplatin treatment. Surprisingly, checkpoint targeting eliminated both checkpoint arrest and checkpoint slippage, and augmented the induction of cell death in interphase without mitotic entry. Taken together, our study, by profiling cell fate determination after cisplatin treatment, reveals new insights into chemoresistance and suggests combinatorial strategies that potentially overcome cancer resistance.

KW - Caffeine

KW - Cell fate

KW - Chemoresistance

KW - Cisplatin

KW - Mg132

UR - http://www.scopus.com/inward/record.url?scp=84966633267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966633267&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8110

DO - 10.18632/oncotarget.8110

M3 - Article

VL - 7

SP - 23383

EP - 23394

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -